Drug Profile


Latest Information Update: 31 Mar 1995

Price : $50

At a glance

  • Originator Apcell
  • Developer Andromaco; Apcell
  • Class Antineoplastics; Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 31 Mar 1995 Discontinued-II for Cancer in USA (Unknown route)
  • 31 Mar 1995 Discontinued-Preclinical for Cancer in Spain (Unknown route)
  • 08 Nov 1994 Phase-II clinical trials for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top